The estimated Net Worth of Susan Laura Smith is at least 478 千$ dollars as of 5 March 2024. Susan Smith owns over 1,682 units of Y-Mabs Therapeutics Inc stock worth over 450,092$ and over the last 3 years Susan sold YMAB stock worth over 27,837$.
Sign up
Susan Smith YMAB stock SEC Form 4 insiders trading
Susan has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Susan sold 1,682 units of YMAB stock worth 27,837$ on 5 March 2024.
The largest trade Susan's ever made was selling 1,682 units of Y-Mabs Therapeutics Inc stock on 5 March 2024 worth over 27,837$. On average, Susan trades about 280 units every 0 days since 2021. As of 5 March 2024 Susan still owns at least 33,918 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Susan Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Susan Smith's mailing address?
Susan's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Insiders trading at Y-Mabs Therapeutics Inc
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over 85,284,951$ worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth 23,554,756$ . The most active insiders traders include James Healy、Thomas Gad、Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of 494,414$. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth 219,000$.
What does Y-Mabs Therapeutics Inc do?
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
What does Y-Mabs Therapeutics Inc's logo look like?
Complete history of Susan Smith stock trades at Y-Mabs Therapeutics Inc
Y-Mabs Therapeutics Inc executives and stock owners
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
CEO & Director -
Claus Moller-San Pedro,
Chief Executive Officer, Director -
Thomas Gad,
Chairman of the Board, President, Founder, Head of Business Development and Strategy -
Thomas Gad,
Founder, Chairman, Pres and Head of Bus. Devel. & Strategy -
Bo Kruse,
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director -
Bo Kruse,
Exec. VP, Sec., Treasurer & CFO -
David Gill,
Independent Director -
James Healy,
Independent Director -
Ashutosh Tyagi,
Independent Director -
Gerard Ber,
Independent Director -
Johan Wedell-Wedellsborg,
Independent Director -
Torben Lund-Hansen,
Senior Vice President, Chief Technical Officer -
Steen Lisby,
Senior Vice President, Chief Medical Officer -
Philip Herman,
Senior Vice President and Chief Commercial Officer -
Mahiuddin Ahmed,
Senior Vice President, Chief Scientific Officer -
Joris Wilms,
Chief Operating Officer, Senior Vice President -
Sue Smith,
Sr. VP & Chief Commercial Officer -
Dr. Torben Lund-Hansen,
Sr. VP & Chief Technical Officer -
Joris Wiel Jan Wilms,
Sr. VP & COO -
Dr. Vignesh Rajah,
Sr. VP & Chief Medical Officer -
Dr. Steen Lisby M.D., M.Sc.,
Sr. VP & Chief Scientific Officer -
Peter P. Pfreundschuh,
CFO and Treasurer -
Gregory S Raskin,
Director -
Ashu Tyagi,
Director -
Mary Tagliaferri,
Director -
Laura Hamill,
Director -
Vignesh Rajah,
SVP & CHIEF MEDICAL OFFICER -
Biotech Ap S Wg,
Director -
Susan Laura Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Michael J Rossi,
PRESIDENT & CEO